Promising New Second-Line Treatment for Mesothelioma
Tislelizumab combined with anlotinib may be a promising new second-line treatment for malignant pleural mesothelioma. A mesothelioma patient in China was successfully treated with these drugs in 2021. The patient has survived for 10 months on this treatment. First-Line Treatments Malignant pleural mesothelioma develops from the thin layer of tissue that covers the lungs and chest wall. It is caused by exposure to asbestos. A healthy pleura is thin and flexible and expands to accommodate the lungs during respiration. In a person with mesothelioma, this membrane becomes thick and stiff, constricting the lungs and causing shortness of breath. First-line treatment for mesothelioma may be chemotherapy, radiation, or therapy. Depending on the health of the patient, more than one treatment might…